Clinical Study on Adoptive Treatment of MDR-TB With Allogeneic γδT Cells
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Brief summary: Allogeneic γδT cells from healthy donor will be administrated intravenously to
patients with the MDR-TB，and then the safety and efficacy of γδT cells will be evaluated.